Skip to main content
SpringerLink
Log in

Role of vasobilation in the antihypertensive and antianginal effects of labetalol: Implications for therapy of combined hypertension and angina

  • Symposium on Combined Alpha- and Beta Blockade in Angina
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Beta-adrenergic blockade is established therapy in the management of both hypertension and angina pectoris. This review evaluates the use of combined alpha-adrenergic and beta-adrenergic blockade for these conditions, with reference to labetalol. There are three major differences between labetalol and propranolol or similar conventional betablockers. First, in the mechanism of the antihypertensive effect, peripheral vasodilation plays a prominent role during the use of labetalol. In particular, acute therapy with labetalol rapidly reduces the blood pressure because of this reduction in the systemic vascular resistance. During prolonged therapy with labetalol over many years, blood pressure remains reduced with a sustained fall in the systemic vascular resistance. Second, in patients with combined hypertension and angina pectoris, fixed doses of labetalol (200 mg twice daily) gave the same blood pressure values, effort tolerance, and nitrate usage as did atenolol 100 mg once daily in a double-blind, double-dummy, crossover study. Labetalol gave higher heart rates at rest and during exercise (both p<0.01). The higher heart rate with labetalol could be an advantage in some patients with effort angina and a disadvantage in others. Third, in hypertensive asthmatics, labetalol appears to have a relative bronchosparing effect, when compared with propranolol. The possession by labetalol of beta2-stimulating qualities (intrinsic sympathomimetic activity) may explain part of the dilating effect and the bronchosparing quality. Thus labetalol 1) lowers blood pressure by a mechanism involving vasodilation, 2) has an equiantianginal effect to atenolol yet at a higher heart rate, and 3) may be bronchosparing. Differences among various beta-blocker may be important in matching the properties of the beta-blocker chosen to the requirements of the individual patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wallin JD, O'Neill WMJr. Labetalol, current research and therapeutic status. Arch Intern Med 1983; 143: 485–490.

    Google Scholar 

  2. Brogden RN, Heel RC, Speight TM, et al. Labetalol: A review of its pharmacology and therapeutic use in hypertension. Drugs 1978; 15: 251–270.

    Google Scholar 

  3. Lund-Johansen P. Short and long-term (six year) hemodynamic effects of labetalol in essential hypertension. Am J Med 1983; 75: 24–31.

    Google Scholar 

  4. Tadepalli AS, Novak PJ: Intrinsic sympathomimetic activity of labetalol. J Cardiovasc Pharmacol 1986; 8: 44–50.

    Google Scholar 

  5. Fagard R, Amery A, Reybrouck T, et al. Response of the systemic and pulmonary circulation to alpha- and beta-receptor blockade (labetalol) at rest and during exercise in hypertensive patients. Circulation 1979; 60: 1214–1219.

    Google Scholar 

  6. Mehta J, Cohn JN. Hemodynamic effects of labetalol on α-and β-adrenergic blocking agent in hypertensive subjects. Circulation 1976; 55: 370–375.

    Google Scholar 

  7. Brittain RT, Levy GP. A review of the animal pharmacology of labetalol, a combined alpha and beta-adrenoceptor blocking drug. Br J Clin Pharmacol 1976; 3 (Suppl): 681–694.

    Google Scholar 

  8. Greenslade FC, Tobias AM, Madison SM, et al. Labetalol binding to specific α- and β-adrenergic sites in vitro and its antagonism of adrenergic responses in vivo. J Mol Cell Cardiol 1979; 11: 803–811.

    Google Scholar 

  9. Dage RC, Hsieh CP. Direct vasodilation by labetalol in anesthetized dogs. Br J Pharmacol 1980; 70: 287–293.

    Google Scholar 

  10. Baum T, Sybertz EJ. Pharmacology of labetalol in experimental a animals. Am J Med 1983; (Suppl): 15–23.

  11. Frishman WH. Properties of labetalol, a combined α- and β-blocking agent, relevant to the treatment of myocardial ischemia. Cardiovasc Drugs Ther 1988; 2: 343–353.

    Google Scholar 

  12. Richards DA, Prichard BNC, Boakes AJ et al. Pharmacological basis for antihypertensive effects of intravenous labetalol. Br Heart J 1977; 39: 99–106.

    Google Scholar 

  13. Fitzgerald JD, Ruffin R, Smedstad KG, et al. Studies on the pharmacokinetics and pharaacodynamics of atenolol in man. Eur J Clin Pharmacol 1978; 13: 81–89.

    Google Scholar 

  14. Holtzman JL, Finley D, Johnson B, et al. The effects of single-dose atenolol, labetalol, and propranolol on cardiac and vascular function. Clin Pharmacol Ther 1986; 40: 268–273.

    Google Scholar 

  15. Trust PM, Rosel EA, Brown JJ, et al. Effect on blood pressure, angiotensin-II, and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: Comparison with propranolol. Br J Clin Pharmacol 1976; 3 (Suppl): 799–803.

    Google Scholar 

  16. Tsukiyama H, Otsuka K, Higuma K. Effects of β-adrenoceptor antagonists on central haemodynamics in essential hypertension. Br J Clin Pharmacol 1982; 13: 269S-278S.

    Google Scholar 

  17. Lund-Johansen P. Hemodynamic consequences of long-term beta-blocker therapy: A 5-year follow-up study of atenolol. J Cardiovasc Pharmacol 1979; 1: 487–495.

    Google Scholar 

  18. Guth BD, Heusch G, Seitelberger R, et al. Mechanism of beneficial effect of β-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res 1987; 60: 738–746.

    Google Scholar 

  19. Mohrman DE, Feig EO. Competition between sympathetic vasoconstriction and metabolic vasodilation in the canine coronary circulation. Circ Res 1978; 42: 79–86.

    Google Scholar 

  20. Buffington CW, Feigl E. Adrenergic coronary vasoconstriction in the dog. Circ Res 1981; 48: 416–423.

    Google Scholar 

  21. Gwirtz PA, Stone HL. Coronary vascular response to adrenergic stimulation in exercise conditioned dogs. J Appl Physiol 1984; 57: 315–320.

    Google Scholar 

  22. Brown BG, Lee AB, Bolson EL, et al. Reflex constriction of significant coronary stenosis as a mechanism contributing to ischaemic left ventricular dysfunction during isometric exercise. Circulation 1984; 70: 18–24.

    Google Scholar 

  23. Feigl EO. The paradox of adrenergic coronary vasoconstriction. Circulation 1987; 76: 737–745.

    Google Scholar 

  24. Mudge GH, Goldberg S, Gunther S, et al. Comparison of metabolic and vasoconstrictor stimuli on coronary vascular resistance in man. Circulation 1979; 59: 544–550.

    Google Scholar 

  25. Berkenboom GM, Abramowicz M, Vandermoten P, et al. Role of alpha-adrenergic coronary tone in exercise-induced angina pectoris. Am J Cardiol 1986; 57: 195–198.

    Google Scholar 

  26. Seitelberg R, Guth BD, Heusch G, et al. Regional alpha2-blockade improves function and flow in the ischemic myocardium during exercise (abstr). J Am Coll Cardiol 1986; 7:252A.

    Google Scholar 

  27. Heusch G, Deussen A. The effects of cardiac sympathetic nerve stimulation on perfusion of stenotic coronary arteries in the dog. Circ Res 1983; 53: 8–15.

    Google Scholar 

  28. Sheridan DJ, Thomas P, Culling W, et al. Antianginal and haemodynamic effects of β1-adrenoceptor blockade. J Cardiovasc Pharmacol 1986; 8(Suppl 2): S144-S150.

    Google Scholar 

  29. Quyyumi AA, Wright C, Mockus L, et al. Effecta of combined alpha and beta adrenoceptor blockade in patients with angina pectoris. A double blind study comparing labetalol with placebo. Br Heart J 1985; 53: 47–52.

    Google Scholar 

  30. Levene DC, Freeman MR: Alpha-adrenoceptor-mediated coronary artery spasm. JAMA 1976; 236: 1018–1022.

    Google Scholar 

  31. Ricei DR, Orlock AE, Cipriano PR, et al. Altered adrenergic activity in coronary arterial spasm: Insight into mechanism based on study of coronary hemodynamles and the electrocardiogram. Am J Cardiol 1979; 43: 1073–1079.

    Google Scholar 

  32. Lassvick CT, Areskog NH. Angina in cold environment. Reactions to exercise. Br Heart J 1979; 42: 396–401.

    Google Scholar 

  33. Winniford MD, Felipchuck N, Hillis LD. Alpha-adrenergic blockade for variant angina: a long-term, double-blind randomized trial. Circulation 1983; 67: 1185–1188.

    Google Scholar 

  34. Chierchia S, Davies G, Berkenboom G, et al. α-Adrenergic receptors and coronary spasm: An elusive link. Circulation 1984: 1: 8–14.

    Google Scholar 

  35. Prida XE, Hill JA, Feldman RL. Systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test rosponses. Am J Cardiol 1987; 59: 1084–1088.

    Google Scholar 

  36. Richardson PJ, Hill LS. Relationship between hypertension and angina pectoris. Br J Clin Pharmacol 1979; 7: 249S-253S.

    Google Scholar 

  37. Hill LS, Monaghan M, Richardson PJ. Regression of left ventricular hypertrophy during treatment with antihypertensive agents. Br J Clin Pharmacol 1979; 7: 255S-259S.

    Google Scholar 

  38. Opherk D, Mall G, Zebe H, et al. Reduction of coronary reserve: A mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation 1984; 69: 1–7.

    Google Scholar 

  39. Maseri A, l'Abbate A, Pesola A, et al. Coronary vasospasm in angina pectoris. Lancet 1977; 1: 713–717.

    Google Scholar 

  40. Chierchia S, Gallino A, Smith G, et al. Role of heart rate in pathophysiology of chronic stable angina. Lance 1984; 2: 1353–1357.

    Google Scholar 

  41. Frishman WH, Klein NA, Klein P, et al. Comparison of oral propanolol and verapamil for combined systemic hypertension and angina pectoris. Am J Cardiol 1982; 50: 1164–1172.

    Google Scholar 

  42. Lubbe WF, White DA. Beneficial effect of labetalol in hypertensive patients with angina pectoris. S Afr Med J 1983; 63: 67–71.

    Google Scholar 

  43. Halprin S, Frishman W, Kirschner M, et al. Clinical pharmacology of the new β-adrenergic blocking drugs. Part II. Effects of oral labetalol in patients with both angina pectoris and hypertension: A preliminary experience. Am Heart J 1980; 99: 388–396.

    Google Scholar 

  44. Frishman WH, Strom JA, Kirschner M, et al. Labetalol therapy in patients with systemic hypertension and angina pectoris: Effects of combined alpha and beta-adrenoceptor blockade. Am J Cardiol 1981; 48: 917–927.

    Google Scholar 

  45. Besterman EMM, Spencer M. Open evaluation of labetalol in the treatment of angina pectoris occurring in hypertensive patients. Br J Clin Pharmacol 1979; 8: 205S-209S.

    Google Scholar 

  46. Opie LH, Jee L, White D. Antihypertensive effects of nifedipine combined with cardioselective beta-adrenergic receptor antagonism by atenolol. Am Heart J 1982; 104: 606–612.

    Google Scholar 

  47. Jee LD, Opie LH. Double-blind trial comparing labetalol with atenolol in the treatment of systemic hypertension with angina pectoris. Am J Cardiol 1985; 56: 551–554.

    Google Scholar 

  48. Schmieder RE, Rueddel H, Neus H, et al. Disparate hemodynamic responses to mental challenge after antihypertensive therapy with β-blockers and calcium entry blockers. Am J Med 1987; 82: 11–16.

    Google Scholar 

  49. Schiffer F, Hartley LH, Schulman CL, et al. Evidence for emotionally-induced coronary arterial spasm in patients with angina pectoris. Br Heart J 1980; 46: 62–66.

    Google Scholar 

  50. Agabiti Rosei E, Brown JJ, Lever AF, et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol. Br J Clin Pharmacol 1976; 3 (Suppl): 809–815.

    Google Scholar 

  51. Flamenbaum W, Weber MA, McMahon FG, et al. Monotherapy with labetalol compared with propranolol. Differential effects by race. J Clin Hypertens 1985; 1: 56–69.

    Google Scholar 

  52. Saunders E, Curry C, Hinds J, et al. Labetalol compared with propranolol in the treatment of black hypertensive patients. J Clin Hypertens 1987; 3: 294–302.

    Google Scholar 

  53. Skinner C, Gaddie J, Palmer KNV. Comparison of intravenous AH 5158 (ibodomide) and propranolol in asthma, Br Med J 1975; 270: 59–61.

    Google Scholar 

  54. George RB, Light RW, Hudson LD, et al. Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with asthma and propranolol sensitivity. Chest 1985; 88: 815–818.

    Google Scholar 

  55. Joekes AM, Thompson FD. Acute haemodynamic effects of labetalol and its subsequent use as an oral hypotensive agent. Br J Clin Pharmacol 1976; 3(Suppl): 789–793.

    Google Scholar 

  56. Dreslinski GR, Messerli FH, Dunn FG, et al. Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension. Circulation 1982; 65: 1365–1368.

    Google Scholar 

  57. Tarazi RC, Dustan HP. Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations. Am J Cardiol 1972; 29: 633–640.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Heart Research Unit, Department of Medicine, University of Cape Town, Observatory, South Africa

    Lionel H. Opie

Authors
  1. Lionel H. Opie
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This paper was assessed by an external Editor

Rights and permissions

Reprints and permissions

About this article

Cite this article

Opie, L.H. Role of vasobilation in the antihypertensive and antianginal effects of labetalol: Implications for therapy of combined hypertension and angina. Cardiovasc Drug Ther 2, 369–376 (1988). https://doi.org/10.1007/BF00054645

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00054645

Key words

Search

Navigation